Analysts Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $35.50

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) has received a consensus recommendation of "Buy" from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $35.50.

Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday, March 17th. Wall Street Zen downgraded Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Finally, Roth Capital initiated coverage on Capricor Therapeutics in a report on Tuesday, May 20th. They issued a "buy" rating and a $31.00 target price on the stock.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock traded up $0.23 during trading on Friday, hitting $10.48. The company's stock had a trading volume of 994,418 shares, compared to its average volume of 1,731,976. The stock's fifty day moving average is $10.46 and its 200 day moving average is $13.33. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The stock has a market capitalization of $478.69 million, a price-to-earnings ratio of -9.89 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The business had revenue of $2.73 million during the quarter, compared to analysts' expectations of $3.16 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. During the same quarter last year, the firm earned ($0.31) EPS. On average, research analysts anticipate that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its holdings in Capricor Therapeutics by 419.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock valued at $855,000 after purchasing an additional 45,381 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Capricor Therapeutics by 74.8% in the fourth quarter. SG Americas Securities LLC now owns 15,317 shares of the biotechnology company's stock worth $211,000 after buying an additional 6,552 shares during the period. Rhumbline Advisers grew its stake in shares of Capricor Therapeutics by 44.4% in the fourth quarter. Rhumbline Advisers now owns 46,083 shares of the biotechnology company's stock valued at $636,000 after buying an additional 14,169 shares in the last quarter. New York State Common Retirement Fund raised its holdings in shares of Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after buying an additional 5,000 shares during the period. Finally, Black Diamond Financial LLC purchased a new stake in shares of Capricor Therapeutics during the 4th quarter valued at about $3,833,000. Institutional investors and hedge funds own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.